Dx IPOs Plummet, SPAC Market Recedes Among Macroeconomic Difficulties

Article By Kelsy Ketchum / July 12, 2022

Managing Director’s Oded Ben-Joseph, PhD, and Paul Mieyal, PhD, were interviewed by 360Dx for their views on capital markets’ current receptiveness towards COVID diagnostics companies and the viability of SPAC’s for life sciences firms.

 

View PDF

Resources

A Shifting Market Environment and Strategies Fueling Innovation in Prostate Cancer Treatment

Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.

Download
Resources

Outcome Capital Life Science Market Pulse, March 2025

Outcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC

Business Continuity Plan | Privacy Policy | Regulation Best Interest

Built by Metropolis